UROV News and Press, Urovant Sciences Ltd. From 06/13/19

Urovant Sciences (NASDAQ: UROV ): Q4 GAAP EPS of -$0.96 misses by $0.01 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019. Recent Business...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019 after...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin will present at the annual Roivant Pipeline Day on June 6, 2019 at 1:50 p.m. ET. ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Jefferies 2019 Healthcare Conference on Tue...

Thinly traded micro cap Urovant Sciences ( UROV +5.1% ) bucks the broad market selloff, albeit on light volume. Detailed results from the Phase 3 EMPOWUR study assessing vibegron in overactive bladder patients were presented yesterday at the American Urological Association Annual Meeti...

Pivotal Phase 3 EMPOWUR study met both co-primary endpoints, with significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively), and a favorable safety and tolerability profile Efficacy observed at ...

Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies f...

By Bill Langbein, Founder SanaCurrents One of the strongest performing biopharmaceutical stocks this year is Evolus ( EOLS ). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then ...